Pay in 4 interest-free payments of $6.03 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
Summary: Retatrutide is an investigational triple receptor agonist (GLP-1, GIP, and glucagon) showing promising early weight-loss and metabolic data in Phase 2 trials, but it is not yet approved in the UK and carries notable side effects and safety uncertainties
Okada, Y
BCBS Federal Employee Program members experienced dramatic cost increases starting in 2025
Phase 2 trial data show dose-dependent increases in resting heart rate, alongside favourable reductions in systolic blood pressure and triglycerides
Its helping me with my energy so far I like it
US$ 20.83
US$ 26.72
.webp)
US$ 23.74
US$ 27.28
US$ 27.14
US$ 21.49
